Abstract
In order to explain the molecular causes of Parkinson’s Disease (PD) it is important to understand the effect that mutations described as causative of the disease have at the functional level. In this special issue, several authors have been reviewing the effects in PD and other parkinsonisms of mutations described in LRRK2, α-synuclein, PINK1-Parkin-DJ-1, UCHL1, ATP13A2, GBA, VPS35, FBOX7 and HTRA2. In this review, we compile the knowledge about other proteins with a more general role in neurodegenerative diseases (MAPT) or for which less data is available due to its recent discovery (EIF4G1, DNAJC13), the lack of structural or functional data (as for PLA2G6 or DNAJC6), or even their doubtful association with the disease (as for GIGYF2, SYNJ1 and SPR). Also the cellular pathways involved in this disease are reviewed, with the goal of having an overview of the effects on the proteins and its possible role in the disease. This knowledge could also serve as the basis for designing tools that may potentially be used as a treatment for the disease, such as inhibitory or activating molecules, as well as other involved in regulating the half-life of the proteins involved.
Keywords: SPR, GIGYF2, PLA2G6, eIF4G1, DNAJC6, SYNJ1, DNAJC13, PARK10, PARK16, MAPT.
Current Protein & Peptide Science
Title:Other Proteins Involved in Parkinson's Disease and Related Disorders
Volume: 18 Issue: 7
Author(s): Fernando Cardona*Jordi Perez-Tur*
Affiliation:
- Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (IBV-CSIC). Calle Jaime Roig 11, Valencia E46010,Spain
- Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (IBV-CSIC). Calle Jaime Roig 11, Valencia E46010,Spain
Keywords: SPR, GIGYF2, PLA2G6, eIF4G1, DNAJC6, SYNJ1, DNAJC13, PARK10, PARK16, MAPT.
Abstract: In order to explain the molecular causes of Parkinson’s Disease (PD) it is important to understand the effect that mutations described as causative of the disease have at the functional level. In this special issue, several authors have been reviewing the effects in PD and other parkinsonisms of mutations described in LRRK2, α-synuclein, PINK1-Parkin-DJ-1, UCHL1, ATP13A2, GBA, VPS35, FBOX7 and HTRA2. In this review, we compile the knowledge about other proteins with a more general role in neurodegenerative diseases (MAPT) or for which less data is available due to its recent discovery (EIF4G1, DNAJC13), the lack of structural or functional data (as for PLA2G6 or DNAJC6), or even their doubtful association with the disease (as for GIGYF2, SYNJ1 and SPR). Also the cellular pathways involved in this disease are reviewed, with the goal of having an overview of the effects on the proteins and its possible role in the disease. This knowledge could also serve as the basis for designing tools that may potentially be used as a treatment for the disease, such as inhibitory or activating molecules, as well as other involved in regulating the half-life of the proteins involved.
Export Options
About this article
Cite this article as:
Cardona Fernando*, Perez-Tur Jordi*, Other Proteins Involved in Parkinson's Disease and Related Disorders, Current Protein & Peptide Science 2017; 18 (7) . https://dx.doi.org/10.2174/1389203717666160311122152
DOI https://dx.doi.org/10.2174/1389203717666160311122152 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets COVID-19: An Opinion of Prevention and Dietary Based Management Hypothesis
Coronaviruses Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) Remifentanil with or without Propofol as Anesthesia Agents for Trans- Vaginal Ultrasonography Oocyte Retrieval (TUGOR) on Pregnancy and Anesthesia Outcomes: A Randomized Controlled Trial
Current Reviews in Clinical and Experimental Pharmacology The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Clinical and Forensic Aspects of Pharmacobezoars
Current Drug Research Reviews Beta-Blocking Agents and Electroconvulsive Therapy
Current Drug Therapy High Throughput Screening and Structure-Activity Relationship Study of Potential α2A-Adrenoceptor Agonists by LANCETM cAMP Assay
Combinatorial Chemistry & High Throughput Screening The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration
Current Molecular Medicine Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents
Current Drug Targets Early Occurrence Cases of Diabetes Mellitus: Clinical Picture in Two Major Tertiary Care Hospitals in India
Current Diabetes Reviews Neurokinin-1 (NK<sub>1</sub>) receptor antagonists as possible therapeutics for psychostimulant use disorders
CNS & Neurological Disorders - Drug Targets Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pediatric Abdominal Trauma
Current Pediatric Reviews “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology